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Introduction 
Respiratory tract infections (RTIs) are a common source of 
morbidity, mortality and utilization of healthcare resources 
(l-4). In terms of the sum of years of life lost and years of 
life lived with a disability (DALYs), lower RTIs contribute 
the greatest burden of disease worldwide (113 million in 
1990) (5). This is more than twice that caused by ischemic 
heart disease (5). Pneumonia is also the leading cause of 
death in some countries (5). 
Three key bacterial pathogens are involved in RTI- 
Streptococcus pneumoniae, Haemophilus influenzae and 
Moraxella catavrhalis. As prescribing for community- 
acquired RTIs is empirical, antibiotic choice should ensure 
adequate coverage of these main pathogens. Surveillance 
studies, such as the Alexander Project (6) indicate that 
antimicrobial resistance is an increasing problem through- 
out the world (7). Such studies show increased prevalence of 
resistance in all key respiratory pathogens to antimicrobial 
agents commonly used to treat community-acquired RTIs. 
Streptococcus pneumoniae 
PENICILLIN RESISTANCE 
Data from the Alexander Project (8) indicate that the 
prevalence of both penicillin-intermediate (penicillin MIC 
0.12-l ,ug ml- ‘) and penicillin-resistant (penicillin MIC 
>2 ,ug ml-‘) strains of S. pneumoniae continues to increase. 
Overall, penicillin non-susceptibility in 1999 was 42.4% 
(16.1% penicillin-intermediate; 26.3 % penicillin-resistant) 
for all isolates tested (9). The prevalence of non-susceptible 
isolates exceeded 40% in 12 of the 23 study centers included 
in the 1999 study: Hong Kong (79.8%), South Africa 
(79.3%), Japan (63.5%), France (62.5%), Saudi Arabia 
(61.9%), Israel (53.8%), Singapore (52.6%), Mexico 
(52.5%), Greece (48.4%), Kenya (48.1%) U.S.A. 
(48.0%) and Spain (47.3%). In contrast, some countries’ 
centers (e.g. for the Czech Republic, Germany and Russia) 
still have relatively low prevalences of penicillin-non- 
susceptible strains-around 10% (9). 
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Between 1992 and 1999 (6-9), in countries where a 
significant prevalence of penicillin-resistant S. pneumoniae 
was first reported (e.g. France and Spain), resistance has 
remained fairly stable. However, data from 1999 indicate 
that there may have been a further upturn in resistance 
(Fig. 1) (9). Data from the U.S.A. indicate a fairly rapid 
and ongoing increase in the prevalence of these strains. 
Italy is perhaps unusual for southern Europe in that the 
prevalence of resistance has remained low, though there 
was a slight increase in 1999 (8,9). 
MACROLIDE RESISTANCE 
There has been a striking increase in the prevalence of 
macrolide-resistant strains of S. pneumoniae (erythromycin 
MIC >l pgmll’) throughout the world (Fig. 2) and with 
prevalences increasing from European centers. The overall 
prevalence of these strains was 31.3% in 1999 compared 
with 9.9% for European and 6.4% for U.S.A. centers in 
1992. For S. pneumoniae isolates tested from Hong Kong, 
Japan, Singapore, France, Belgium, Italy, Spain and the 
U.S.A., macrolide resistance exceeded 30% in 1999. In 
many countries macrolide resistance is highly associated 
with penicillin resistance but in Europe macrolide resistance 
among penicillin-susceptible isolates is particularly high in 
Italy (28.1%) and Belgium (20.0%). Somewhat lower but 
increasing prevalences have been found in France (14.5%), 
Greece (ll.O%), Austria (8.6%) Spain (8.3%) the U.K. 
(5.7%) and Switzerland (5.6%) (9). The values for 
erythromycin, clarithromycin and azithromycin are almost 
identical (8,9). 
QUINOLONE RESISTANCE 
A recent study in Canada indicates that, though the 
prevalence of quinolone-resistant strains of S. pneumoniae 
is currently low (1.7%), it is increasing, probably as a result 
of the more widespread use of these agents, such as 
ciprofloxacin (10). Even with quinolone resistance defined 
relatively conservatively (ofloxacin MIC 28 pg ml-‘), there 
has been a sporadic isolation of these strains in Europe, 
with prevalences of between 1 and 3% reported in Ireland, 
Switzerland, Spain, Germany and Poland between 1997 
and 1999 (7-9). 
Haemophilus influenzae 
The principal mechanism of resistance in H. injuenzae is 
fl-lactamase production. In the 1999 Alexander Project, the 
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FIG. 1. Increase in the prevalence of penicillin-non- 
susceptible strains (MIC O.l2->2pgmll’) of 
S. pneumoniae between 1992 and 1999 (6-9). 4: France; 
0: Spain; A: U.S.A.; x : U.K.; a: Italy. 
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FIG. 2. Increase in the prevalence of macrolide-resistant 
strains of S. pneumoniae between 1992 and 1999 (6,7,10). 
n : France; A: Italy; A: U.S.A.; 0: Spain; x : U.K. 
overall prevalence of p-lactamase production was 20.4%, 
with high prevalences (>20%) in the U.S.A. (34.5%), 
France (29.3%), Saudi Arabia (24.7%), Singapore 
(24.0%), Mexico (23.7%) Israel (21.4%), the U.K. 
(21.2%) and Hong Kong (20.2%) (9). The prevalence of 
/3-lactamase production among U.S.A. isolates is consis- 
tently higher than that found among European isolates (9). 
There is a wide variation in the prevalence of p-lactamase- 
producing strains of H. injuenzae throughout Europe 
though, in general, prevalences remain fairly low. In 1999, 
prevalences as low as 6.9% were reported in Italy and the 
Czech Republic, with low prevalences also found in 
Slovakia (6.8%), Poland (7.4%), Switzerland (8.4%) 
Germany (9.3%) and Greece (9.5%) (9). Higher preva- 
lences were reported in Belgium (10.9%) Spain (15.6%), 
Portugal (15.8%) and the Republic of Ireland (17.1%). 
Moraxella catarrhalis 
As for H. influenzae, the principal mechanism of resistance 
in M. catarrhalis is b-lactamase production. The prevalence 
of /?-lactamase-producing strains of M. catarrhalis is 
extremely high throughout Europe, generally greater than 
90%: /3-lactamase production was 93.4% in isolates 
collected during the 1999 Alexander Project (7,9). 
Consequences of antimicrobial 
resistance in RTI 
The most obvious consequence of resistance is that there 
will be more cases of clinical failure. Initially, these will be 
seen after oral therapy, where blood levels achieved are low 
in comparison with those following intravenous or intra- 
muscular dosing. Hand-in-hand with clinical failure comes 
persistent colonization. For pneumococci, at least, where 
transmission is from the nasopharynx, colonization will 
lead to further spread of resistant pathogens. 
Increased levels of resistance and clinical failure, 
undoubtedly, have an impact on the cost of managing 
respiratory infections and pharmacoeconomic studies are 
beginning to identify the costs associated with the manage- 
ment of infections caused by resistant pathogens (11). 
Clearly, we need to review the clinical utility of agents 
currently used to treat RTIs. 
What can be done to reduce 
resistance? 
The aims of antibiotic therapy should be threefold: (i) to 
maximize the opportunity for clinical cure, (ii) to eradicate 
the infecting organism, and (iii) to reduce the potential for 
the development and spread of resistance. Educational 
initiatives may help to increase awareness of the need to 
prescribe antibiotics appropriately. For patients who do 
require antibiotics, it is crucial to maximize the efficacy of 
current agents. Two of the ways in which this can be 
achieved are by identifying the various factors which 
influence efficacy, such as pharmacokinetic and pharmaco- 
dynamic (PK/PD) relationships, and through the re- 
evaluation of guidelines to minimize or eliminate the use 
of sub-optimal agents. Complete eradication of the patho- 
gen from various sites can also reduce the risk of the spread 
of resistant pathogens. In addition, good infection control 
practices can help to prevent transmission. The availability 
of a new pneumococcal vaccine will also have an important 
impact. 
Conclusions 
It is now well accepted that the worldwide prevalence of 
resistance in S. pneumoniae and other respiratory pathogens 
is increasing. While results from published clinical trials 
suggest that resistance in S. pneumoniae has not compro- 
mised the clinical efficacy of some penicillins (when used at 
the correct dose), emerging data indicate that resistance is 
compromising the efficacy of other routinely used anti- 
microbials, such as some oral cephalosporins, macrolides 
and older fluoroquinolones. In the light of these reports, 
there appears to be a need to re-assess current empirical 
therapeutic recommendations for community-acquired 
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RTIs to encompass pneumococci, H. inJEuenzae and M. 
catarrhalis. Furthermore, we urgently require measures that 
will help to reduce the prevalence of resistance. 
There are concerns that it may be already too late to 
apply interventions to reduce resistance levels and regain 
previous quality and cost of care. From the articles 
presented here, we can conclude that antibiotics must be 
prescribed only when warranted i.e. for bacterial infections, 
and that clinicians must follow clear therapeutic guidelines. 
If the use of an antibiotic is appropriate, the dose and 
frequency of administration should be based on PKjPD 
considerations. The use of PKjPD principles will help to 
ensure that susceptible pathogens and those with emerging 
resistance are eradicated, and will thus also minimize the 
potential for continued carriage and the spread of resistant 
pathogens. 
These measures alone may not be enough, however, and 
it is crucial that those working in this field consider other 
potential interventions, such as infection control and 
vaccination programs. 
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